NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, has launched an investigation into whether the officers or directors of Adamas Pharmaceuticals, Inc. (NASDAQ: ADMS) breached their fiduciary duties or violated the federal securities laws in connection with the company’s acquisition by Supernus Pharmaceuticals, Inc. (NASDAQ: SUPN).
Click here to learn more and participate in the action.
On October 12, 2021, Adamas announced that it had entered into an agreement to be acquired by Supernus in a transaction valued at approximately $400M. Pursuant to the merger agreement, Adamas stockholders will receive $8.10 in cash plus two Contingent Value Rights (“CVRs”) worth up to $1.00 for each share of Adamas common stock owned. The CVRs are payable upon the achievement of certain net sales thresholds of GOCOVRI, Adamas’ lead product. The deal is scheduled to close in the fourth quarter of 2021.
Bragar Eagel & Squire is concerned that Adamas’ board of directors oversaw an unfair process and ultimately agreed to an inadequate merger agreement. Accordingly, the firm is investigating all relevant aspects of the deal and is committed to securing the best result possible for Adamas’ stockholders.
If you own shares of Adamas and are concerned about the proposed merger, or you are interested in learning more about the investigation or your legal rights and remedies, please contact Melissa Fortunato or Alexandra Raymond by email at email@example.com or telephone at (646) 860-9157, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.